Document is current
Any future updates will be listed below
-
Authors
Krupp, Lauren https://orcid.org/0000-0001-7003-807X
Banwell, Brenda
Chitnis, Tanuja https://orcid.org/0000-0002-9897-4422
Deiva, Kumaran
Gaertner, Jutta
Ghezzi, Angelo
Huppke, Peter
Waubant, Emmanuelle
DeLasHeras, Virginia
Azmon, Amin
Karan, Rajesh
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01892722 at ClinicalTrials.govDocuments that mention this clinical trial
Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIG<i>MS</i>
https://doi.org/10.1136/jnnp-2019-321124
Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIG<i>MS</i> Study
https://doi.org/10.1136/bmjno-2021-000215
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG<i>MS</i>study
https://doi.org/10.1136/jnnp-2019-322138
-
Funding
Funding for this research was provided by:
Novartis Pharma AG, Basel, Switzerland (NA)
- License Information
